Clinical Pharmacokinetics of Sparfloxacin

@article{Shimada1993ClinicalPO,
  title={Clinical Pharmacokinetics of Sparfloxacin},
  author={J. Shimada and T. Nogita and Y. Ishibashi},
  journal={Clinical Pharmacokinetics},
  year={1993},
  volume={25},
  pages={358-369}
}
  • J. Shimada, T. Nogita, Y. Ishibashi
  • Published 1993
  • Medicine
  • Clinical Pharmacokinetics
  • SummarySparfloxacin is a recently developed fluoroquinolone. The drug has shown potent antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria, glucose nonfermenters, anaerobes, Legionella spp., Mycoplasma spp., Chlamydia spp. and Mycobacterium spp. Methicillin-resistant Staphylococcus aureus is also susceptible to sparfloxacin.Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose. This is… CONTINUE READING
    67 Citations
    Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.
    • 16
    • PDF
    Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone Antibacterials
    • 99
    • Highly Influenced
    Quinolone Antibacterials
    • 28
    A Critical Review of the Fluoroquinolones
    • 266
    • Highly Influenced
    A Review of New Fluoroquinolones
    • 35
    Absorption Interactions With Fluoroquinolones
    • 81

    References

    SHOWING 1-10 OF 30 REFERENCES
    [Clinical and bacteriological study of sparfloxacin on bacterial prostatitis].
    • 3
    In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    • 59
    Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue.
    • 35
    In vitro activity of AT-4140 against clinical bacterial isolates.
    • 91
    • PDF